Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty
NCT06792539
Recruiting
The goal of this clinical trial is to evaluate the safety and effectiveness of the Polymotion Hip Resurfacing (PHR) System compared to total hip arthroplasty, for adults who require hip resurfacing arthroplasty due to 1) non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, traumatic arthritis, or 2) mild dysplasia/developmental dislocation of the hip (DDH) up to Crowe Grade 1.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
08/04/2025
Locations: Sinai Hospital / LifeBridge Health, Baltimore, Maryland
Conditions: Osteoarthritis of the Hip, Degenerative Joint Disease of Hip, Dysplasia; Hip
Register for Updates
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2025
Locations: Velocity Clinical Research - Rockville- Site Number : 8400036, Rockville, Maryland
Conditions: Asthma
Register for Updates
Open-Label Extension of EryDex Study IEDAT-04-2022
NCT06664853
Recruiting
This is an international, multi-center, prospective, open-label, non-comparative study to provide EryDex treatment to ataxia telangiectasia (A-T) patients who complete the IEDAT-04-2022 trial on the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
08/04/2025
Locations: The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland
Conditions: Ataxia Telangiectasia
Register for Updates
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895
Recruiting
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/04/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Register for Updates
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
NCT06517888
Recruiting
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Vestibular Schwannoma
Register for Updates
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Maryland, Baltimore /ID# 242216, Baltimore, Maryland
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
The Protrieve PROTECTOR Study
NCT06495996
Recruiting
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: MedStar Union Memorial Hospital, Baltimore, Maryland
Conditions: Venous Thromboembolism, Deep Venous Thrombosis
Register for Updates
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
NCT06440707
Recruiting
Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Johns Hopkins Medical Center, Baltimore, Maryland
Conditions: Acute Ischemic Stroke
Register for Updates
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Headlands PharmaSite /ID# 257208, Baltimore, Maryland
Conditions: Migraine
Register for Updates
RevCore for In Stent Thrombosis
NCT06394739
Recruiting
The purpose of this research is to collect information about how the RevCore Thrombectomy Catheter works to treat stent blockages.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Maryland, Baltimore, Maryland
Conditions: In-stent Thrombosis
Register for Updates
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744
Recruiting
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: University of Maryland, Baltimore /ID# 259538, Baltimore, Maryland
Conditions: Follicular Lymphoma (FL)
Register for Updates
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
NCT06159725
Recruiting
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of ant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Persistent Infection, Cystic Fibrosis
Register for Updates